Life Sciences Archive » September, 2015

Life Sciences - September, 2015

290 articles

• Sanofi Vaccine Customers Get Class Cert. In Antitrust Case
• Class Cert. Denied Again In Ensure Drinkers' False Ad Suit
• 1st Circ. Gives Whistleblower Redo In Covidien FCA Suit
• Sandoz, UTC Settle Generic Remodulin Patent Suit
• Avon Beats Class Cert. Attempt In Anti-Aging Products Row
• Sirona Dental Investor Challenges $5.5B Sale To Dentsply
• Fed. Circ. Won't Rehear $15M Prosthetics Patent Suit
• Medtronic Escapes Investors' Claims Of Tainted Studies
• FTC Gives $3.3B Wright, Tornier Deal Conditional OK
• Hagens Berman To Appeal Sanctions In Thalidomide Litigation
• Deals Rumor Mill: Perrigo, Synaptics, Brown-Forman
• Nixon Peabody, Mintz Levin Can't Escape Malpractice Row
• Calif. Judge Tosses Invisalign False Ad Class Action
• Synergetics Investor Takes Aim At Valeant Deal
• A Look At The Legality Behind Daraprim's Price Spike
• Lessons From Key Players In Guidant MDL
• Approach To '2nd Medical Use' Claims Varies Across EU
• TriReme Medical Cleared In Catheter IP Trial, Attys Say
• Bass 'Patent Troll' Ally Seeks Help Targeting Depomed IP
• Abbott Wants Developmental Delays Kept From Depakote Trial
• Pelvic Mesh Users Slam Ethicon's Coaching Claims
• Pfizer Unit Pays $194M To End NJ Superfund Cleanup Row
• Hedge Fund Manager Again Targets Biogen's MS Drug Patent
• Corvus Pharma Raises $75M To Help Cancer Treatment R & D
• FDA Warning Wire: Workout Booster, Label Lies, Hemorrhoids
• Nexium Buyers Fight Drugmakers' Bid For Costs After Loss
• Feds Push Against Split Trial Over Meningitis Outbreak
• Fed. Circ. Affirms PTAB Finding In Cancer Drug Interference
• LifeScan May Be Why Patent Exhaustion Had No Pulse In Nero
• Pa. Jury Clears J&J Over Children's Motrin Claims
• Sen. Sanders Urges US To Back Drug Patent Exception
• Hawaii High Court Seeks Comments On Marijuana Ethics Rule
• Pa. Children's Motrin Case Heads To The Jury
• PTAB Decision Not To Sanction Bass Shifts Focus To Capitol
• A Cybersecurity Checklist For In-House Counsel
• Safe Harbor Protects Supplier Of Active Ingredient For ANDA
• Dinner Chat Doesn't Merit Inventor Credit In Patent Fight
• Judge Pares Humana's Claims In RICO Suit Against Medtronic
• Janssen Trims Two Claims From Remicade Biosimilar Battle
• Novartis Sclerosis Drug Patent Gets Axed In AIA Review
• Intervening Rights Defense Dooms Cancer Drug IP Claims
• AAI Backs Mylan's Appeal Of Doryx Product-Hopping Suit
• Sidley-Led Cytomx Seeks $106M IPO To Fund Cancer Drugs
• AbbVie Calls Docs Sought In Pay-For-Delay Suit Privileged
• SEC Charges 5 For Insider Trading On Gilead Acquisition
• Jury Awards Logtale $5M For IKOR's Investment Breach
• Steris-Synergy Merger Case — A Missed Opportunity
• Law360 Names Most Feared Plaintiffs Firms Of 2015
• Acacia Unit Settles Surgical Patent Suits With Zimmer
• PTAB Won't Sanction Bass For AIA Reviews Of Drug Patents
• Merck Fights To Toss Alaska AG's Suit Over Vioxx
• FDA Urged To Review More Data On Essure Side Effects
• Cardinal Health To Exit Antitrust Suit With $1.2M Deal
• 11 Firms To Guide Offerings Totaling $1.4B To End September
• 1st Circ. Told Warner Chilcott Paid Actavis To Kill Competition
• OPINION: Have Big Law Firms Lost Their Way?
• 6 IP Boutiques Punching Above Their Weight
• Bayer Didn't Violate FTC Supplements Settlement, Judge Rules
• Endo Sheds Drugs To Ease FTC Concerns Over $8B Par Buy
• $4.5M Wright Hip Implant Verdict Cut To $1M By Calif. Judge
• Hedge Fund Accused Of Extortion Loses AIA Review Bid
• IRS Urges Court To Uphold Mylan's $100M Tax Bill
• Strategies For Drug Cos. Facing Parallel Gov't Investigations
• Experts Say Ethicon Didn't Disclose Pelvic Mesh Dangers
• Kickstarting Information Governance: 3 Ideal Pilot Projects
• FTC Hits Fla. Weight-Loss Company With False Ad Suit
• FTC's Unusual Theory Made Steris Case An Uphill Battle
• Generics Maker Can't Duck Baxter Suit Over Brevibloc
• Biogen Can't Demand Royalties After Patent Expired, Suit Says
• Fed. Circ. Upholds Shire's Victory In Generic Vyvanse Suit
• 250 Philly Risperdal Suits May Be Time-Barred, Judge Says
• EPA Proposes Rule To Stop Pharmaceutical Flushing
• Nature's Way Slammed Over Move To Toss Ginkgo Pill Suit
• FTC Loses Bid To Block $1.9B Steris-Synergy Deal
• 10 Men Charged Over Steroid, Money Laundering Conspiracy
• 3rd Circ. Won't Rethink Lamictal Pay-For-Delay Ruling
• Perrigo Gets Claims Over CMS Drug Reimbursements Tossed
• Clinton Aims To Tackle Out-Of-Pocket Health Costs
• GSK Gets Wellbutrin Pay-For-Delay Antitrust Suit Nixed
• Actos Pay-For-Delay Class Action Gets The Boot
• Ethicon Says Pelvic Mesh Plaintiffs' Counsel Coached Doctors
• Senate Passes Bill To Increase Transparency In Gov't Deals
• AstraZeneca Hits Mylan With Patent Suit Over Cancer Generic
• DLA Piper Doubles Hamburg Office With Bird & Bird Raid
• Takeda Manipulated Gout Drug Clinical Trial, FCA Suit Claims
• Stock Tipper Can't Nix SEC Settlement After Newman
• FDA Regulation Catches Up To Next-Gen Gene Sequencing
• FDA Says Essure Birth Control Complaints Have Spiked
• Mylan Countersues Perrigo Over $27B Hostile Takeover Bid
• J&J's Ethicon Unit Defends Pelvic Mesh In Dallas Trial
• Ethicon Mounts 4th Circ. Appeal Of $3M Pelvic Mesh Verdict
• Medicare Group Opposes Carveout For Drug Patents
• Costco Urges Court To Toss Generic Lipitor Labeling Suit
• Aggrenox Buyers Blast Discovery Bid In Antitrust MDL
• FDA Warning Wire: Rust, Cancer Risks, Trial Dangers
• Horizon Pharma Seeks To Block IGI's Pennsaid Generic
• J&J Fights Class Cert. In 'Natural' Baby Wash False Ad Row
• 2nd Circ. Shows Difficulties Robinson-Patman Claims Face
• The 4 Firms In-House Counsel Fear The Most
• Supplement Maker Says Nutrex Is Infringing Trademark
• Mylan Takes Benicar Patent Dispute To The Supreme Court
• Don't Miss It: Hot IPOs & Firms We're Following
• Bayer CropScience Reaches $5.6M Deal Over Plant Explosion
• Mylan To Nix Anti-Takeover Tool Used Against Teva
• Investors Slam Valeant's Bid To Duck Insider Trading Suit
• SEC Says Stem Cell Research Co. Execs Misled Investors
• Vinson & Elkins Nabs 2 IP Pros From Perkins Coie
• Bayer Sues Drug Info Co. For Posting False Mirena Price
• Amgen Sues Hospira Over Biosimilar Info, Notice
• Stryker Slams Attys' Fee Bid In $6.8M TCPA Class Action Deal
• Lawmakers Want Indian IP, Food Barriers Curtailed In Summit
• The FDA's Risk-Based Approach To Medical App Enforcement
• 3rd Circ. Urged To Revive Avandia Suit Against GSK
• Boston Scientific Says Plaintiff Trying To Reopen Discovery
• Arthrex Asks High Court To Weigh Obviousness Review
• Pfizer, FDA Updating Pregnancy Caution On Zoloft Label
• Plaintiff With Dark Past Drops Boston Scientific Mesh Suit
• CORRECTED: Lenox's Counsel Sanctioned In Medtronic Antitrust Row
• J&J Pelvic Device Gets 1st Court Test In Dallas Trial
• U. of Colo. Says Amgen Withholding Arthritis Med Royalties
• Bard, Whistleblower Agree To End Catheter FCA Suit
• 5th Circ. Upholds VA Med Malpractice Judgment For Widow
• Luitpold Entitled To Some Damages In $120M Contract Dispute
• Provigil Buyers Want $141M In Fees For Cephalon Deal
• Calif. Jury Clears Hyland's In $255M False Ad Trial
• Real Estate Rumors: Moody's, Aduro Biotech, Brookhill
• A Possible Regulatory Reboot For US Biotech
• 2nd Circ. Stays Recall Of Pregnancy Tests In False Ad Row
• Hyland's 'Sugar Pill' False Ad Trial Wraps With $255M Ask
• Gatorade Owner No Fan Of 'Haterade,' Sues Creator Over TM
• Medtronic Infuse Injury Plaintiff Takes Appeal To Top Court
• Fixodent Users Try To Revive Zinc Sickness MDL Against P&G
• Insurance Co. Claims Limited Liability In Bard Pelvic Mesh Row
• Pa. Judge Trims Claims In Ex-Teva Atty's Wrongful Firing Suit
• Gilead Sues Lupin Over Plans To Produce Generic Tamiflu
• 4 Takeaways From FDA's Biosimilars Briefing
• Real Estate Rumors: Goldman, Jabal Omar, Baxalta
• Perrigo Rejects Mylan Offer Again, Files Suit
• China's Biostime Buys Into $1.2B Australian Vitamin Maker
• GeneDx Says Rival Startup Poaches Staff For Trade Secrets
• FTC Slams Supplement Co. Recusal Bid In Labeling Suit
• Crafting Method Of Treatment Claims To Avoid Multiple Actors
• Ex. Pfizer Co. Beats Much Of Defective Poultry Vaccine Suit
• Nutraceutical's Homeopathics Just 'Sugar Pills,' Suit Says
• O'Melveny & Myers Nabs Life Sciences Co-Head
• J&J Unit Wants $1.2M Pelvic Mesh Judgment Wiped Out
• Sens. Urged To Unveil Painkiller Probe Of Purdue, J&J, Endo
• Cooley Snags Ex-WilmerHale Team In London
• Amgen Inks $300M Deal For Dutch Drugmaker
• UAE Investors Dodge SEC's $3.7M Insider Trading Suit
• Otsuka Hits Hetero With Patent Suit Over Generic Diuretic
• Dentsply Buying Rival Sirona For $5.5B In Dental Co. Merger
• Provigil Buyers Again Say Class Cert. Order Needs Tweaking
• Obama Taps FDA Deputy Commissioner To Lead Agency
• Lupin Pushes 4th Circ. To Block Alaska AG's Info Demands
• Meningitis Outbreak Worker Seeks Split From Murder Case
• Allergan Fights To Keep IPR Extortion Fight In Federal Court
• Cooley-Led Seattle Genetics Nets $552M In Follow-On
• Allergan Seeks To Block Pfizer Unit's Generic Dry-Eye Drug
• FDA Warning Wire: Pigeons Invade Pharma Plant
• Sens. Float 2 Bills To Crack Down On Pay-For-Delay Deals
• Solving Law Firm Staffing Problems Through Innovation
• Pregnancy Test Maker Denies False Ad Campaign In 2nd Circ.
• Takeda Says Most Actos Claimants Want In On $2.4B Deal
• FDA Panel Backs Collegium's 'Abuse-Deterrent' Painkiller
• Drug Supplier Hits VA With Suit Over Potential Debarment
• Insurer Says Mass. High Court Needn't Hear Atty Conflict Row
• Wyeth Says Medicaid Didn't Trigger Protonix Discounts
• Depomed Urges Stockholders To Snub Latest Horizon Offer
• DLA Piper Adds Ex-Finnegan IP Managing Partner In Boston
• FDA Slashes Forecast On Alerts For Counterfeit Drugs
• 'No Basis In Law' For FDA Pill Size Limits, Group Says
• Rival Must Pay For Infringing AngioScore Cath IP, Jury Told
• Possible Effects Of Mass. Nonresident Pharmacy Licensure
• GSK False Ad Suit Over Teva's Generic Wellbutrin Frozen
• Goodwin-Led Dimension Therapeutics Preps $115M Debut
• Adderall Buyers Slam Drugmaker's Class Cert. Objections
• US Endoscopy Gets PTAB To Nix CDX Biopsy Brush Patent
• Olympus Hit With 3rd Pa. Suit Claiming Device Spread Cancer
• Covidien Investor Lambasts Deal Over $43B Medtronic Merger
• Baker Botts Adds Trio Of IP Partners From Vinson & Elkins
• Amgen Heads To High Court Over Handling Of Worker Stock
• Daiichi Asks Justices To Settle Fight Over Disclaimed Drug IP
• Celgene Calls Kyle Bass' AIA Review Bids 'Harassment'
• Biotech Co. Cellceutix Hyped Sham Drugs, Class Action Says
• 3 Life Sciences Cos. Set To Price IPOs After Long Market Lull
• Husch Blackwell Snags Ex-Leydig Voit IP Atty
• SIGA Seeks Another Extension Of Ch. 11 Exclusivity Period
• Drugmakers Have Tough Task In Quest For AIA Exemption
• Mylan, Ranbaxy Slam Bid To Change Provigil Class Cert.
• J&J, Bayer Sued For Downplaying Risks Of Xarelto
• Kansas City Fed Says Pot Credit Union Can't Have Account
• FDA Nixes Bid For 'Special Flexibility' For Orphan Drugs
• Barnes & Thornburg Adds Trial Atty From Greenberg Traurig
• Pfizer Loses Lyrica Patent Fight In UK Court
• Ex-Harvard Doc Defends Hyland's In $350M False Ad Trial
• AbbVie, Besins Told To Give Judge Disputed Docs In FTC Fight
• FDA Strengthens Warning For Type 2 Diabetes Meds
• Diet Supplement Co.'s Ex-Owner Headed To Prison For Fraud
• Allergan Allows Amneal To Market Generic Namenda In 2020
• King & Spalding Lures Off-Label Expert From FDA
• Prograf Maker Says Class Cert. Doesn't Clear 1st Circ.'s Bar
• Reckitt Launches Counterclaims In Mucinex Antitrust Suit
• Litigation Financing May Ease Your Year-End Cash Crunch
• SEC Settles Insider-Trading Charges Over GE Deal
• Whole Foods Customers Ready To Drop Homeopathy Claims
• Amgen, Sandoz Duel Over En Banc Bids In Biosimilars Fight
• NJ Benicar Side-Effect Suits Combined In Atlantic County
• USTR Seeks Data On 'Notorious' IP Infringement Markets
• Which Cos. Are Most Likely To Benefit From Innovation Box?
• Children's Motrin Didn't Cause Skin Condition, Pa. Jury Hears
• Morgan Lewis Adds Ex-Teva Counsel As White Collar Partner
• FDA's Primary Weapon In Food Fights: Warning Letters
• Pacira Sues FDA Over Constraints On Pain Drug's Marketing
• Thermo Fisher Sanctioned Over Flubbed Depo In Fraud Suit
• FDA Warning Wire: 'Adulterated' Devices, 'Modified' Tobacco
• 9th Circ. Axes Ex-InterMune CEO's Suit Over Conviction News
• Baker & McKenzie Adds Partners And Counsel In Miami, DC
• House Passes E-Warranty Bill, Renews Health Programs
• SEC Affirms Bar On CPA Charged With Leaking Sanofi Deal
• J&J Blasted Over Children's Motrin Warning At Trial Kickoff
• LifeCell Sues To Escape LifeNet Graft Patent Threat
• Fed. Circ. Nixes Ivera Loss In Disinfectant Cap Patent Case
• FTC Says AbbVie Can't Shield Docs In Pay-For-Delay Fight
• Cymbalta Plaintiffs To Appeal To 9th Circ. After Trial Losses
• Stryker Asks Judge To OK $6.8M TCPA Class Action Deal
• Pharma Reps Slam PTAB Over 'Skewed' Procedural Rules
• Mylan To Take Proposal Directly To Perrigo Shareholders
• 5th Circ. Kicks Stryker Foot Implant Suit To State Court
• 3 Life Sciences Cos. Polish $300M In Anticipated Floats
• Concordia's $3.5B Deal Grows Rare Disease Drug Portfolio
• Legal Vs. Illegal Drugs In Event Cancellation Policies
• Hyland's Sells Placebos, Doctor Says In $350M False Ad Trial
• Genzyme Seprafilm Admissions Muted In New DOJ Settlement
• FTC Says It Has Evidence To Block $2B Steris-Synergy Deal
• Sanofi Pays $2.4M To Kill Cancer Drug Sales Class Action
• Texas Justices Again Stay Out Of Fen-Phen Referral Fee Fight
• Malpractice Challenge In $50M Eli Lilly Settlement Stands
• Artificial Joint Co. Hid Issues Before $121M IPO, Suit Claims
• Impax Board Dodges Suit Over Bugs In Its Drugs, For Now
• Past Defeats Bode Ill For J&J In Pa. Children's Motrin Trial
• 6th Circ. Told Ethicon Surgical Stapler Suit Belongs In US
• GSK Tells 3rd Circ. To Uphold Dismissal Of Avandia Suit
• Inside The Summer's Hottest M&A Plays
• Allergan To Pay $300M For Glaucoma Treatment Developer
• EPA's Hazardous Waste Rule Is Just What The Doctor Ordered
• Hyland's Faces Disappointed Mom In $350M False Ad Trial
• Motrin Plaintiffs Say Bartlett Doesn't Block All Defect Claims
• GSK Fights To Block Expert For Reed Smith Atty's Widow
• Despite Denial, Bass Launches New Attack On Acorda Patents
• Bass Blasts Sanctions Bid, Says Drug AIA Reviews Aid Public
• Genzyme Pays $32.5M Criminal Fine For Seprafilm Marketing
• Judge Rejects $3M CVS Wage Settlement With Pharmacists
• Avalanche, Investors Ask To Consolidate Stock Drop Suits
• VisionAid Asks Mass. High Court About Atty Conflict Claim
• J&J Unit Can't Get Judge To Reconsider Bid To Nix TCPA Suit
• Sandoz Launches First Biosimilar At 15% Discount
• Brinks Gilson Adds Womble Carlyle, Katten Muchin Attys
• TIG Asks 6th Circ. To Nix $9M Stryker Knee Ruling
• 340B Omnibus Guidance Could Lead To Increased Drug Costs
• Homeopathic Co. CEO Defends Testing At $350M False Ad Trial
• Supreme Court Lifts Stay On Akebia, FibroGen Patent Fight
• Female Workers Win Conditional Cert In $100M Sex-Bias Row
• Trial Wins Boost Eli Lilly In Cymbalta Cases As MDL Bid Looms
• 1st Circ. Ruling Doesn't Apply In Labeling Suit, CVS Says
• Debevoise, Fox Rothschild Rep Lannett In $1.2B Drug Co. Buy
• Mass. Judge Says Pfizer Whistleblower Suit Likely To Proceed
• Pharmacia Shakes Schools' Toxic Light Ballasts Suit
• Real Estate Rumors: Gilead Sciences, Starwood, TGM
• PTAB Denies Hedge Fund's Bid For Biogen Patent Review
• Abbott, AbbVie Lied To Court In Depakote Suit, Plaintiff Says
• 2nd Circ. Stays Recall Of Misleading Swiss Pregnancy Tests
• Amgen Can't Block Sandoz Biosimilar At Fed. Circ.
• Skadden-Led Valeant Inks Deal For Surgical Device Maker
• Patent Invalidity Rates: The Summertime Blues Continue
• The Tension Between Corporate Opportunity And Innovation
• PTAB Misconduct Rule Won't Deter Hedge Fund Attacks
• Feds Tells 9th Circ. Ex-Oriole Can't Block Trading Evidence
• Supreme Court Halts Discovery In Anemia Drug Patent Suit
• FDA Warning Wire: Powdered Caffeine, Kim Kardashian
• Plaintiffs Fight 3rd Bid To Toss Protein Powder Ad Suit
• Judge Urged To Ax 'Tortured' Zoloft Birth Defect Testimony
• Merck Beats Back Whistleblower's FCA Claims Over Integrilin
• Claims, Experts Cut From Hip Implant Bellwether Case
• PTAB To Scrutinize Hedge Fund's Use Of AIA Review Program
• Eli Lilly Cleared By Jury In Cymbalta Withdrawal Suit
• Eisai Says FDA Wrongly Denied Drug Exclusivity Extension
• Zimmer Calls Knee Implant MDL Trial Plan A Waste Of Time
• J&J Says Cherokees' Risperdal Suit Should Stay Federal
• How Sequenom Lost Patent Protection For Fetal DNA Test